Phacetoperane for treating of attention deficit hyperactivity disorder
AssigneeNLS Pharmaceutics AG
InventorsEric KONOFAL, Bruno FIGADERE
Life of this patent
Estimating the term…
Abstract
The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane.
Claims5
1-10. (canceled)
A pharmaceutical composition comprising a therapeutically effective amount of levophacetoperane, or a pharmaceutically acceptable salt thereof, for the treatment of attention deficit hyperactivity disorder (ADHD) and a pharmaceutical acceptable excipient.
Dependencies are inferred from the claim text.